First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in
patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin
lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D)
Secondary Objectives:
To characterize the safety profile of SAR442257 To characterize the pharmacokinetics (PK)
profile of SAR442257 To evaluate the potential immunogenicity of SAR442257 To assess
preliminary evidence of antitumor activity